Kai Ming Medical-B (02500.HK): Further updates on unauthorized loans and pledge deposits continue to be suspended
Gelonghui, April 16, 丨 Qiming Medical-B (02500.HK) issued an announcement. As of the date of this announcement, an unauthorized pledge deposit of RMB 100 million provided by Hangzhou Qiyi (a wholly-owned subsidiary of the company) to guarantee the Hangzhou Kuntai loan (due to expire on April 14, 2024) has been released from the relevant bank and further withdrawn by the company from the bank. Furthermore, as of the date of this announcement, Hangzhou Qiyi has received interest income of RMB 2,0506 million on these deposits. On the date of this announcement, the Group's previous pledges were made to guarantee the loan and on the date of the forensic investigation announcement
Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21%
Venus Medtech (Hangzhou) (HKG:2500) narrowed its loss attributable to owners of the parent to 720.9 million yuan in 2023, from 1.06 billion yuan in the year-ago period, according to a March 28 filing
Qiming Medical-B (02500) released annual results, gross profit of 389 million yuan, a year-on-year increase of 23.95%
Qiming Medical-B (02500) announced its annual results for the year ended December 31, 2023. The group...
VENUS MEDTECH-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
VENUS MEDTECH-B: DATE OF BOARD MEETING AND CONTINUED SUSPENSION OF TRADING
Zhongtai Securities: Edward Evoque received FDA approval and continues to be optimistic about the commercialization prospects of tricuspid valve intervention
Recently, Edward Life Sciences announced that its tricuspid valve product Evoque has been approved by the FDA for marketing. This is the first FDA-approved tricuspid valve replacement product.
Kai Ming Medical-B received additional guidance from the Stock Exchange to continue suspending trading
Kai Ming Medical-B (02500) announced that the company received a letter from the Stock Exchange on February 9, 2024, according to which the Exchange issued additional guidance on the resumption of trading to the company after the death of Mr. Lau Wan-yee: to re-comply with the requirements of section 3.10 (1), section 3.10A, section 3.21 and section 3.27A of the listing rules relating to the composition and chairmanship of the board of directors and its board committee (if applicable). Trading of the company's shares continues to be suspended.
Kai Ming Medical-B (02500) received additional guidance from the Exchange to resume trading and continued to be suspended
According to Zhitong Financial App News, Qiming Medical-B (02500) announced that the company received a letter from the Stock Exchange on February 9, 2024. According to this, the Stock Exchange issued additional guidance on resuming trading to the company after the death of Mr. Lau Yun-yi: re-complying with the requirements of section 3.10 (1), section 3.10A, section 3.21 and section 3.27A of the listing rules relating to the composition and chairman of the board committee (if applicable). Trading of the company's shares continues to be suspended.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Qiming Medical-B (02500.HK): Wang Fei appointed as Chief Financial Officer
Gelonghui January 4 | Qiming Medical-B (02500.HK) issued an announcement. Wang Fei has been appointed as Chief Financial Officer with effect from January 4, 2024. Trading of the Company's shares has been suspended on the Stock Exchange since 9:00 a.m. on November 23, 2023, and will continue to be suspended until further notice.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Venus Medtech Gets Trading Resumption Guidance
The Hong Kong Stock Exchange required Venus Medtech (Hangzhou) (HKG:2500) to conduct an investigation and independent review as part of its guidance to resume trading. The forensic investigation into
Kai Ming Medical-B (02500.HK) receives guidance on the resumption of trading from the Stock Exchange
Gelonghui, December 27 | Qiming Medical-B (02500.HK) announced that on December 20, 2023, the company received a letter from the Stock Exchange setting out the guidelines for resuming trading of the company's shares (collectively referred to as the resumption guidelines). According to the resumption guidelines, the company shall: (a) conduct a special audit and conduct an appropriate supervisory investigation with respect to (a) the provision of loans to Mr. Zi and Mr. Tsang and (b) other financial flows between the Group and Mr. Zi, Mr. Tsang and/or any entity owned or controlled separately or jointly by them, as may be discovered during the special review, and publish the findings and take appropriate remedial action; (b)
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Venus Medtech Concludes Probe Into Funds Loaned to Ex-Directors; Declares Remedial Action
Venus Medtech (Hangzhou) (HKG:2500) concluded its internal investigation into funds loaned to two former executive directors – Zhenjun Zi and Frank Zeng – who both resigned on Nov. 20. The probe ident
Qiming Medical-B (02500.HK) will be suspended from November 23 until insider information is published
Gelonghui November 23丨Qiming Medical-B (02500.HK) announced that trading of the company's shares on the Hong Kong Stock Exchange has been temporarily suspended since 9:00 a.m. on November 23, 2023 (Thursday), pending publication of an announcement constituting inside information about the company.
Qiming Medical-B (02500.HK) was suspended for a short time this morning
Gelonghui November 23丨Qiming Medical-B (02500.HK) announced that trading of the company's H shares will be temporarily suspended starting at 9:00 a.m. today (23/11/2023).
Venus Medtech to Market Valgen Medtech's Heart Valve Repair System Across China
Heart-valve maker Venus Medtech (Hangzhou) (HKG:2500) said it has inked a "strategic" deal with Hangzhou Valgen Medtech that will see Venus market the latter's transcatheter mitral valve repair system
Qiming Medical-B (02500.HK) and Dejin Medical reached an exclusive strategic marketing cooperation agreement to accelerate the promotion and popularization of valvular heart disease diagnosis and treatment technology in China
Gelonghui November 22|Qiming Medical-B (02500.HK) announced that on November 22, 2023, the company and Hangzhou Dejin Medical Technology Co., Ltd. (“Dejin Medical”) jointly announced on November 22, 2023, that they have reached an exclusive strategic marketing agreement on Dejin Medical's DragonFly transducer mitral valve clip system (“DF”). The two sides will carry out in-depth commercial cooperation after DF is approved to enter the market. Dejin Medical will make full use of the marketing and sales network covering nearly 500 top three hospitals that Keiming Medical has established over many years, perfect market access channels, and a sound clinical technical training system
No Data